Navigation Links
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.
Date:7/22/2011

MILLBROOK, N.Y., July 22, 2011 /PRNewswire/ -- Egenix, Inc. -- Donald Fresne, CEO of Egenix, announced that the board approved the appointment of Nils Bergenhem, PhD as President and Chief Scientific Officer.  Dr. Bergenhem brings 16 years of drug development experience to the company and has successfully built and maintained international drug-discovery collaborations between equally-sized companies, as well as between biotech and major pharmaceutical companies.  Two out of three collaborations produced drug candidates moving into clinical development.  He was Vice President of Research & Development, and Chief Scientific Officer at CPEX Pharmaceuticals, Inc, an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products prior to its sale early this year.  He previously held leadership positions at Escoublac, Inc, Adipogenix, Inc, the Institute for Diabetes Discovery, and OSI Pharmaceuticals.  Dr. Bergenhem received his B.S. in Chemistry at Linkoping University and Ph.D. in Biochemistry from Umea University in Sweden.

"Egenix approach to treating cancer has the potential to prevent uncontrolled cancerous cell growth, while not affecting normally growing cells," said Nils Bergenhem.  "I am very excited to join Egenix, and help drive these programs forward to clinical application."

About Egenix, Inc:

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factors" eIF4E and eIF2a, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes.  The company licensed this technology from Harvard Medical School in 2007.  eIF4E and eIF2a are attractive cancer therapeutic targets because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by these translation initiation factors.  Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction.  For more information visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
2. The Newly Combined Axcan and Eurand Announce Name Change to Aptalis
3. Global Pharm Holdings Group Obtains Business License for its Newly Established Joint-Venture in Jinan City
4. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
5. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
6. Breakaway From Cancer® Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients
7. Zimmer Showcases Newly Acquired Line of Surgical Power Tools at 2011 AAOS Annual Meeting
8. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
9. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
10. Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy
11. Capital BlueCross Newly Designed Health Care Reform Web Portal Features New Videos, Interactive Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, ... grew 34 percent to $6.7 billion and can be expected to grow ... next five years, from $6.7 billion in 2016, to $22.6 billion in ... able to purchase cannabis without a doctor,s recommendation. Voters in ...
(Date:3/27/2017)... 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus ... Invictus MD is pleased to announce it has received ... on the TSX Venture Exchange.  Receiving ... year of significant achievements for Invictus-MD. Some of which ... at AB Laboratories Inc. ("AB Labs"), a Licensed Producer ...
(Date:3/27/2017)... The staggering cost of cancer treatment means ... to the latest treatment options against cancer. Even among ... have inadequate or no health insurance and are oftentimes ... to modern cancer treatment is almost non-existent for cancer ... The mission statements of pharmaceutical and biotech companies often ...
Breaking Medicine Technology:
(Date:3/27/2017)... Conshohocken, PA (PRWEB) , ... March 27, 2017 ... ... in business simulation -centric training, today announced the launch of a new ... corporate strategy, having the skills needed to execute that strategy, and the actual ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... California (PRWEB) , ... March 27, 2017 , ... The ... to its customers. First National Capital has added 10 new sales professionals over the ... its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... a settlement agreement to resolve the pending litigation between itself and 1800 Vending ... District of Utah). , “I am thrilled to announce that we have now ...
(Date:3/27/2017)... ... March 27, 2017 , ... The homeowner improvement and repair market is ... DIY and unlicensed contractors for renovations is also on the rise. Per a 2017 ... and of those, 42% failed to use a licensed contractor.(2) The risks associated with ...
Breaking Medicine News(10 mins):